| Literature DB >> 35125885 |
Sirui Song1, Liqin Chen1, Qianqian Ning2, Danying Zhu1, Feng Qiu2, Guang Li2, Hong Zhang3, Tingting Xiao1, Guohui Ding4, Min Huang1.
Abstract
PURPOSE: Kawasaki disease (KD) is an acute systemic vasculitis mainly found in the medium-sized arteries, especially the coronary arteries. Immune system is involved in the pathogenesis of acute KD in children, but the functional differences in the immune system between healthy children and KD patients remain unclear. PATIENTS AND METHODS: A total of 190 KD patients and 119 healthy controls were recruited for the next-generation sequencing of 512 targeted genes from 4 immune-related pathways. Subsequently, the peripheral blood mononuclear cells (PBMCs) were isolated. RNA sequencing of the LPS treated PBMCs from additional 20 KD patients and 20 healthy controls was used to examine the differentially expressed genes (DEGs). Then, an expression quantitative trait locus (eQTL) analysis combined with previously analyzed RNA data were used to examine the DEGs. Finally, the serum levels of 13 cytokines were detected before and after LPS treatment in 40 samples to confirm the findings from eQTL analysis.Entities:
Keywords: Kawasaki disease; cytokines; inflammation; innate immunity; next generation sequencing
Year: 2022 PMID: 35125885 PMCID: PMC8807868 DOI: 10.2147/IJGM.S343225
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
The Number of SNVs Included in Differentially Expressed Genes Between KD Patients and Controls
| Gene Name | SNVs |
|---|---|
| CD84 | 62 |
| ELF5 | 2 |
| IL-10 | 12 |
| PIK3CG | 38 |
| PRKCQ | 26 |
| PTPN6 | 19 |
| SMAD2 | 57 |
Significant Differentially Expressed Genes Between KD Patients and Controls After RNAseq
| Gene_Name | Gene_Id | fc | pval | qval |
|---|---|---|---|---|
| GIT1 | ENSG00000108262 | 1.931794085 | 1.41E-06 | 0.016026 |
| MIR500B | ENSG00000239057 | 5.054199512 | 3.43E-06 | 0.023294 |
| RUNX3 | ENSG00000020633 | 2.573926017 | 5.80E-06 | 0.028173 |
| PLEKHG1 | ENSG00000120278 | 1.703894538 | 8.29E-06 | 0.034766 |
| SRCAP | ENSG00000080603 | 3.24041503 | 9.20E-06 | 0.034766 |
| PLXND1 | ENSG00000004399 | 3.520021248 | 1.22E-05 | 0.04161 |
Figure 1Enrichment analysis of DEGs related to the physiological development and function in KD patients and controls.
Figure 2Enrichment analysis of DEGs in disease disorder of KD patients and controls.
eQTL Analysis for the Examination of DEGs
| GeneSymbol | GeneID | Foldchange | Pvalue | Qvalue | SNVChromosome | SNVSite | SNVAccession | RefAllele | AltAllele | eQTLpvalue | eQTLslope |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIK3CD | ENSG00000171608 | 3.245557 | <0.01 | 0.022091 | chr1 | 9,784,423 | rs11121484 | C | T | 0.04 | −15.5955 |
| PIK3CD | ENSG00000171608 | 3.245557 | <0.01 | 0.022091 | chr1 | 9,788,153 | rs1141402 | G | A | <0.01 | −15.2027 |
| ITPR3 | ENSG00000096433 | 2.995176 | <0.01 | 0.041427 | chr6 | 33,638,180 | rs2229634 | C | T | 0.01 | 2.50358 |
| PRKCZ | ENSG00000067606 | 2.206851 | <0.01 | 0.067363 | chr1 | 1,148,100 | rs34108055 | G | C | 0.02 | 3.85754 |
| MAP2K1 | ENSG00000169032 | 2.828066 | <0.01 | 0.067363 | chr15 | 67,361,308 | rs7162912 | T | G | 0.05 | −3.33218 |
| MAP2K1 | ENSG00000169032 | 2.828066 | <0.01 | 0.067363 | chr15 | 67,407,899 | rs1438386 | G | A | 0.01 | 4.2629 |
| ITGB2 | ENSG00000160255 | 2.612719 | <0.01 | 0.07445 | chr21 | 46,330,628 | rs2280965 | C | T | 0.03 | 13.775 |
| MAVS | ENSG00000088888 | 2.341154 | <0.01 | 0.115362 | chr20 | 3,684,022 | rs611847 | A | G | 0.02 | −3.73908 |
| MAVS | ENSG00000088888 | 2.341154 | <0.01 | 0.115362 | chr20 | 3,684,729 | rs625372 | T | C | 0.02 | −3.94639 |
| OXT | ENSG00000101405 | 2.732799 | <0.01 | 0.116585 | chr20 | 3,682,242 | rs45472900 | C | T | <0.01 | 8.47991 |
| CDC25B | ENSG00000101224 | 2.521221 | <0.01 | 0.123854 | chr20 | 3,668,082 | rs656635 | G | T | 0.04 | −8.13729 |
| CDC25B | ENSG00000101224 | 2.521221 | <0.01 | 0.123854 | chr20 | 3,675,333 | rs3746638 | G | A | 0.02 | −5.0302 |
| CDC25B | ENSG00000101224 | 2.521221 | <0.01 | 0.123854 | chr20 | 3,675,498 | rs709012 | T | G | 0.01 | −5.95212 |
| CDC25B | ENSG00000101224 | 2.521221 | <0.01 | 0.123854 | chr20 | 3,677,736 | rs673114 | T | G | 0.02 | −5.0302 |
| MAP4K1 | ENSG00000104814 | 2.088039 | <0.01 | 0.138198 | chr19 | 39,398,631 | rs3136644 | A | G | <0.01 | 11.3568 |
| MAP4K1 | ENSG00000104814 | 2.088039 | <0.01 | 0.138198 | chr19 | 39,398,649 | rs3136645 | T | C | <0.01 | 8.36483 |
| MAP4K1 | ENSG00000104814 | 2.088039 | <0.01 | 0.138198 | chr19 | 39,399,195 | rs1044284 | A | G | <0.01 | 9.63068 |
| MYBBP1A | ENSG00000132382 | 2.02601 | <0.01 | 0.169123 | chr17 | 5,412,361 | rs8079034 | C | T | 0.03 | 7.0365 |
| MYBBP1A | ENSG00000132382 | 2.02601 | <0.01 | 0.169123 | chr17 | 5,412,473 | rs8079727 | A | C | 0.02 | 7.36876 |
| MYBBP1A | ENSG00000132382 | 2.02601 | <0.01 | 0.169123 | chr17 | 5,412,822 | rs16954813 | G | A | 0.02 | 7.46041 |
| MYBBP1A | ENSG00000132382 | 2.02601 | <0.01 | 0.169123 | chr17 | 5,425,077 | rs11651270 | T | C | 0.02 | 7.58837 |
| DYRK1B | ENSG00000105204 | 2.146684 | <0.01 | 0.183556 | chr19 | 39,399,195 | rs1044284 | A | G | 0.05 | 4.1065 |
| MIR146B | ENSG00000202569 | 2.258973 | <0.01 | 0.19091 | chr10 | 1.05E+08 | rs943037 | C | T | 0.04 | 12.6514 |
| MIR146B | ENSG00000202569 | 2.258973 | <0.01 | 0.19091 | chr10 | 1.05E+08 | rs10430665 | C | T | 0.04 | 12.6514 |
| MIR146B | ENSG00000202569 | 2.258973 | <0.01 | 0.19091 | chr10 | 1.05E+08 | rs10786736 | G | C | 0.04 | 12.6514 |
| MIR146B | ENSG00000202569 | 2.258973 | <0.01 | 0.19091 | chr10 | 1.05E+08 | rs17094683 | G | T | 0.04 | 12.6514 |
Figure 3DEGs associated with SNVs involved in physiological development and function.
Figure 4DEGs associated with SNVs function in disease order.
Figure 5Expression of immunoregulation related DEGs decreased in the KD patients.
Figure 6Expression of cytokines in the PBMCs from KD patients and controls before and after LPS stimulation (A–M).